Advertisement

Breast Cancer Research and Treatment

, Volume 49, Issue 1, pp 41–50 | Cite as

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

  • Hyun Cheol Chung
  • Sun Young Rha
  • Joon Oh Park
  • Nae Choon Yoo
  • Joo Hang Kim
  • Jae Kyung Roh
  • Jin Sik Min
  • Kyong Sik Lee
  • Byung Soo Kim
  • Jin Ju Kim
Article

Abstract

The plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and menstruation phases (follicular, ovulatory, luteal) were determined by FSH/LH levels. uPA, PAI-1, and uPAR levels were at the nadir during ovulatory phase. uPA level was highest at follicular phase while PAI-1 level was highest at luteal phase. In comparison between pre- and post-menopause states, uPA and uPAR levels were higher in post-menopause state while PAI-1 level was higher in pre-menopause state. In breast cancer patients, uPA, PAI-1, and uPAR positive rates were low when we use the menopause-state-unmatched cut-off points. As we adjusted the cut-off points by menopause states, the PAI-1 positivity increased mainly in post-menopause cancer patients. These findings suggest that there is a minor but possible sequential change of these molecules during menstruation cycle which might blur the pathological positivity in pre-menopause cancer patients. The pathological elevation of PAI-1 was well detected in post-menopause cancer patients, but this elevation did not correlate with tumor burden such as number of metastatic sites or metastatic location. In conclusion, adjustment of physiological changes of uPA, PAI-1, and uPAR is required in determining pathological elevation of the plasma levels in cancer patients, especially in females.

uPA PAI-1 uPAR plasma menstruation breast cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–336, 1991CrossRefPubMedGoogle Scholar
  2. 2.
    Vassalli JD, Baccino D, Belin D: A cellular binding site for the Mr 55,000 form of the plasminogen activator, urokinase. J Cell Biol 100: 86–92, 1985.CrossRefPubMedGoogle Scholar
  3. 3.
    Ellis V, Behrendt N, Dano K: Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266: 12752–12758, 1991PubMedGoogle Scholar
  4. 4.
    Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN: Plasminogen activator inhibitors: hormonally regulated serpines. Moll Cell Endocrinol 68: 1–19, 1990CrossRefGoogle Scholar
  5. 5.
    Cubelis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079–1085, 1990PubMedGoogle Scholar
  6. 6.
    Olson D, Pollanen J, Hoyer-Hansen G: Internalization of the urokinase plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267: 9129–9133, 1991Google Scholar
  7. 7.
    Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Femmelly JJ, Lijnen H: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827–6829, 1990PubMedGoogle Scholar
  8. 8.
    Janicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gossner W, Graeff H: Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4, 69–78, 1990CrossRefGoogle Scholar
  9. 9.
    Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Janicke F, Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101–6105, 1992PubMedGoogle Scholar
  10. 10.
    Yamamoto M, Sawaya R, Mohanam S, Bindal AK, Bruner JM, Oka K, Rao VH, Tamonaga M, Nicholson GL, Rao JS: Expression and localization of urokinase-type plasminogen activator in human astrocytoma in vivo. Cancer Res 54: 3656–3661, 1994PubMedGoogle Scholar
  11. 11.
    Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K, Brunner N: Urokinase and plasminogen activator type-1 in pulmonary adenocarcinoma. Cancer Res 54: 120–123, 1994PubMedGoogle Scholar
  12. 12.
    Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, de Boer A, Welvaart K, van de Velde CJH, van Krieken JHJM, Verheijen JH, Lamers CBHW, Verspaget HW: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065–4071, 1994PubMedGoogle Scholar
  13. 13.
    Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521, 1993PubMedGoogle Scholar
  14. 14.
    Fockens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Janicke F, Klijn JGM: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648–1658, 1994PubMedGoogle Scholar
  15. 15.
    Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195–208, 1993CrossRefPubMedGoogle Scholar
  16. 16.
    Bouchet C, Spyratos F, Martin PM: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398–405, 1994PubMedGoogle Scholar
  17. 17.
    Foekens J, Look MP, Peters HA, van Putten WLJ, Portengen H, Klijn JGM: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751–756, 1995PubMedGoogle Scholar
  18. 18.
    Buo L, Meling GI, Karlsrud TS, Johansen HT, Aasen AO: Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorecal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 26: 1133–1138, 1995CrossRefPubMedGoogle Scholar
  19. 19.
    Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR: Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 53: 1788–1793, 1993PubMedGoogle Scholar
  20. 20.
    Casslen B, Bossmar T, Lecander I, Astedt B: Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 30A: 1302–1309, 1994CrossRefPubMedGoogle Scholar
  21. 21.
    Song KS, Lee A, Choi JR, Kwon OH: Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis. Throm Haemost 74: 864–867, 1995Google Scholar
  22. 22.
    Hildenbrand R, Dilger I, Horlin A, Stutte HJ: Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Path Res Pract 1991: 403–409, 1995Google Scholar
  23. 23.
    Modlich U, Kaup FJ, Augustin HG: Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Lab Invest 74: 771–780, 1996PubMedGoogle Scholar
  24. 24.
    Albers A, Thie M, Hohn HP, Denker HW: Differential expression and localization of integrins and CD44 in the membrane domains of human uterine epithelial cells during the menstrual cycle. Acta Anat 153: 12–19, 1995PubMedGoogle Scholar
  25. 25.
    Hrushesky WJM, Bluming AZ, Gruber SA, Sothern RB: Menstrual influence on surgical cure of breast cancer. Lancet ii: 949–952, 1989CrossRefGoogle Scholar
  26. 26.
    Oliver DJ, Ingram DM: Timing of surgery during the menstruation cycle for breast cancer: possible role of growth factors. Eur J Cancer 31A: 325–328, 1995CrossRefPubMedGoogle Scholar
  27. 27.
    Nguyen M, Watanabe H, Budson BE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancer. J Natl Cancer Inst 86: 356–361, 1994PubMedGoogle Scholar
  28. 28.
    Lin RY, Argenta PA, Sullivan KM, Adzick NS: Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients. Clin Cancer Res 1: 327–331, 1995PubMedGoogle Scholar
  29. 29.
    Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochem Biophys Acta 1221: 211–214, 1994CrossRefPubMedGoogle Scholar
  30. 30.
    Jensen PH, Christensen EI, Ebbesen P, Gliemann J, Andreasen PA: Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell Reg 1: 1043–1056, 1990Google Scholar
  31. 31.
    Grunaudo V, Hauert J, Kruithof EKO: Diurnal variation of the fibrinolytic system. Thromb Haemostasis 59: 495–499, 1988Google Scholar
  32. 32.
    Koelbl H, Kirchheimer JK, Tata G, Christ G, Binder BR: Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Obstet Gynecol 72: 252–256, 1988PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Hyun Cheol Chung
    • 1
  • Sun Young Rha
    • 1
  • Joon Oh Park
    • 1
  • Nae Choon Yoo
    • 1
  • Joo Hang Kim
    • 1
  • Jae Kyung Roh
    • 1
  • Jin Sik Min
    • 1
  • Kyong Sik Lee
    • 1
  • Byung Soo Kim
    • 1
  • Jin Ju Kim
    • 2
  1. 1.Yonsei Cancer Research Institute, Yonsei Cancer Center, Department of Internal Medicine, General SurgeryYonsei University College of MedicineSeoulKorea
  2. 2.Department of Clinical PathologyInha University College of MedicineSungnamKorea

Personalised recommendations